PT2675480T - Métodos para preparação de conjugados - Google Patents

Métodos para preparação de conjugados

Info

Publication number
PT2675480T
PT2675480T PT12705761T PT12705761T PT2675480T PT 2675480 T PT2675480 T PT 2675480T PT 12705761 T PT12705761 T PT 12705761T PT 12705761 T PT12705761 T PT 12705761T PT 2675480 T PT2675480 T PT 2675480T
Authority
PT
Portugal
Prior art keywords
conjugates
preparation
methods
Prior art date
Application number
PT12705761T
Other languages
English (en)
Inventor
Fishkin Nathan
Miller Michael
Li Wei
Singh Rajeeva
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45755579&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2675480(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of PT2675480T publication Critical patent/PT2675480T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
PT12705761T 2011-02-15 2012-02-15 Métodos para preparação de conjugados PT2675480T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161443062P 2011-02-15 2011-02-15
US201161443092P 2011-02-15 2011-02-15
US201161483499P 2011-05-06 2011-05-06

Publications (1)

Publication Number Publication Date
PT2675480T true PT2675480T (pt) 2019-04-15

Family

ID=45755579

Family Applications (1)

Application Number Title Priority Date Filing Date
PT12705761T PT2675480T (pt) 2011-02-15 2012-02-15 Métodos para preparação de conjugados

Country Status (30)

Country Link
US (11) US8765740B2 (pt)
EP (6) EP3498303A1 (pt)
JP (8) JP6049642B2 (pt)
KR (6) KR20140010076A (pt)
CN (5) CN103702686B (pt)
AU (5) AU2012231640B2 (pt)
BR (2) BR112013020540B1 (pt)
CA (4) CA2824864C (pt)
CY (2) CY1117340T1 (pt)
DK (2) DK2675480T3 (pt)
ES (2) ES2717657T3 (pt)
HK (1) HK1186686A1 (pt)
HR (2) HRP20160164T1 (pt)
HU (2) HUE028736T2 (pt)
IL (6) IL279304B (pt)
LT (1) LT2675480T (pt)
ME (1) ME02381B (pt)
MX (2) MX343337B (pt)
MY (2) MY169448A (pt)
PL (2) PL2675480T3 (pt)
PT (1) PT2675480T (pt)
RS (2) RS58620B1 (pt)
RU (4) RU2748733C2 (pt)
SG (4) SG191965A1 (pt)
SI (2) SI2675480T1 (pt)
SM (1) SMT201600099B (pt)
TW (1) TWI617555B (pt)
UA (1) UA120696C2 (pt)
WO (3) WO2012128868A1 (pt)
ZA (2) ZA201305386B (pt)

Families Citing this family (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8288557B2 (en) 2004-07-23 2012-10-16 Endocyte, Inc. Bivalent linkers and conjugates thereof
CA2893252C (en) 2005-08-24 2018-05-29 Immunogen, Inc. Process for preparing antibody maytansinoid conjugates
US9138484B2 (en) 2007-06-25 2015-09-22 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
SG2014009138A (en) 2009-02-05 2014-03-28 Immunogen Inc Novel benzodiazepine derivatives
KR101947176B1 (ko) 2009-06-03 2019-02-12 이뮤노젠 아이엔씨 접합 방법
CN107019804A (zh) 2010-04-15 2017-08-08 西雅图基因公司 靶向吡咯并苯并二氮杂卓结合物
AU2011239525B2 (en) 2010-04-15 2015-04-09 Medimmune Limited Pyrrolobenzodiazepines used to treat proliferative diseases
SG191965A1 (en) 2011-02-15 2013-08-30 Immunogen Inc Methods of preparation of conjugates
EP2691155B1 (en) 2011-03-29 2018-11-14 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
CN103987718A (zh) 2011-09-20 2014-08-13 斯皮罗根有限公司 作为非对称二聚体pbd化合物用于内含在靶向结合物中的吡咯并苯并二氮杂卓
CN103987384A (zh) 2011-10-14 2014-08-13 西雅图基因公司 吡咯并苯并二氮杂卓和靶向结合物
KR101961976B1 (ko) 2011-10-14 2019-03-25 시애틀 지네틱스, 인크. 피롤로벤조디아제핀 및 표적 접합체
US9388187B2 (en) 2011-10-14 2016-07-12 Medimmune Limited Pyrrolobenzodiazepines
WO2013053873A1 (en) 2011-10-14 2013-04-18 Spirogen Sàrl Pyrrolobenzodiazepines
US9717803B2 (en) 2011-12-23 2017-08-01 Innate Pharma Enzymatic conjugation of polypeptides
EP2848686A4 (en) * 2012-04-04 2016-01-20 Perseus Proteomics Inc CONJUGATE OF ANTI-CDH3 (P-CADHERINE) ANTIBODY AND MEDICAMENTS
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
JP6423340B2 (ja) 2012-05-15 2018-11-14 シアトル ジェネティクス，インコーポレイティド 自己安定化リンカー結合体
WO2014009426A2 (en) 2012-07-13 2014-01-16 Innate Pharma Screening of conjugated antibodies
EP2887965A1 (en) * 2012-08-22 2015-07-01 ImmunoGen, Inc. Cytotoxic benzodiazepine derivatives
US10035817B2 (en) 2012-10-04 2018-07-31 Immunogen, Inc. Method of purifying cell-binding agent-cytotoxic agent conjugates with a PVDF membrane
EP2906253B9 (en) 2012-10-12 2019-04-10 ADC Therapeutics SA Pyrrolobenzodiazepine - anti-psma antibody conjugates
EP2906297B1 (en) 2012-10-12 2017-12-06 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
ME03486B (me) 2012-10-12 2020-01-20 Medimmune Ltd Pirolobenzodiazepini i njihovi konjugati
ES2680153T3 (es) 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
WO2014057118A1 (en) * 2012-10-12 2014-04-17 Adc Therapeutics Sarl Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
ES2703151T3 (es) 2012-10-12 2019-03-07 Adc Therapeutics Sa Conjugados de anticuerpos de pirrolobenzodiazepinas
CN105102004B (zh) * 2012-10-12 2019-01-25 Adc疗法责任有限公司 吡咯并苯并二氮杂卓-抗cd22抗体结合物
KR20200003278A (ko) 2012-10-12 2020-01-08 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨주게이트
PT2906296T (pt) * 2012-10-12 2018-06-01 Medimmune Ltd Conjugados de pirrolobenzodiazepina-anticorpo
AU2013328673B2 (en) 2012-10-12 2017-07-13 Medimmune Limited Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
US10036010B2 (en) 2012-11-09 2018-07-31 Innate Pharma Recognition tags for TGase-mediated conjugation
KR20150083121A (ko) * 2012-11-12 2015-07-16 레드우드 바이오사이언스 인코포레이티드 화합물, 및 컨쥬게이트의 제조방법
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
BR112015014669B1 (pt) 2012-12-21 2023-09-26 Medimmune Limited Compostos pirrolobenzodiazepinas, conjugados compreendendo os mesmos e uso destes para tratar uma doença proliferativa
CN105246894A (zh) * 2012-12-21 2016-01-13 斯皮罗根有限公司 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
SG11201504887TA (en) 2012-12-21 2015-07-30 Bioalliance Cv Hydrophilic self-immolative linkers and conjugates thereof
EP2968596B1 (en) * 2013-03-13 2019-03-06 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
MX2015011367A (es) 2013-03-13 2015-12-16 Seattle Genetics Inc Ciclodextrina y formulaciones de conjugados anticuerpo-farmaco.
BR112015021965B1 (pt) 2013-03-13 2022-05-03 Medimmune Limited Conjugados e compostos de pirrolobenzodiazepinas, composição farmacêutica, uso dos mesmos para o tratamento de uma doença proliferativa e método de síntese dos ditos compostos
HUE042373T2 (hu) 2013-03-13 2019-06-28 Seattle Genetics Inc Aktív szenes szûrés benzodiazepin ADC-k tisztítására
US10611824B2 (en) 2013-03-15 2020-04-07 Innate Pharma Solid phase TGase-mediated conjugation of antibodies
US10071169B2 (en) 2013-06-20 2018-09-11 Innate Pharma Enzymatic conjugation of polypeptides
JP6744212B2 (ja) 2013-06-21 2020-08-19 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． ポリペプチドの酵素的結合
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
MX2016002574A (es) 2013-08-28 2016-06-14 Stemcentrx Inc Nuevos moduladores del homologo 6 (sez6) y metodos de uso.
SG11201601375VA (en) * 2013-08-28 2016-03-30 Stemcentrx Inc Engineered anti-dll3 conjugates and methods of use
CN105848671B (zh) 2013-08-28 2019-12-13 艾伯维施特姆森特克斯有限责任公司 位点特异性抗体缀合方法和组合物
US9988408B2 (en) 2013-09-02 2018-06-05 Hangzhou Dac Biotech Co., Ltd. Cytotoxic agents for conjugation to a cell binding molecule
GB201317981D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3054983B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3054986B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
KR102538993B1 (ko) 2013-10-15 2023-06-02 씨젠 인크. 개선된 리간드-약물 컨쥬게이트 약물동력학을 위한 peg화된 약물-링커
WO2015123265A1 (en) 2014-02-11 2015-08-20 Seattle Genetics, Inc. Selective reduction of proteins
AU2015218633A1 (en) 2014-02-21 2016-09-01 Abbvie Stemcentrx Llc Anti-DLL3 antibodies and drug conjugates for use in melanoma
EP3125943A4 (en) * 2014-04-04 2017-12-06 Merck Sharp & Dohme Corp. Phosphate based linkers for intracellular delivery of drug conjugates
SG11201609357PA (en) * 2014-05-20 2016-12-29 Immunogen Inc Methods for characterizing and treating acute myeloid leukemia
CN106661124A (zh) * 2014-06-20 2017-05-10 荷商台医(有限合伙)公司 抗叶酸受体α(FRA)抗体‑药物缀合物及其使用方法
WO2016008112A1 (en) 2014-07-16 2016-01-21 Medshine Discovery Inc. Linkers and application towards adc thereof
MA40539A (fr) * 2014-09-02 2016-03-10 Immunogen Inc Procédés de formulation de compositions de conjugués anticorps-médicaments
TW201613930A (en) 2014-09-03 2016-04-16 Immunogen Inc Cytotoxic benzodiazepine derivatives
TW201609152A (zh) * 2014-09-03 2016-03-16 免疫原公司 包含細胞結合劑及細胞毒性劑之偶聯物
TWI757759B (zh) * 2014-09-03 2022-03-11 美商免疫原公司 細胞毒性苯并二氮呯衍生物
MY186334A (en) 2014-09-12 2021-07-12 Genentech Inc Anti-her2 antibodies and immunoconjugates
GB201416112D0 (en) * 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CA2957148A1 (en) * 2014-09-17 2016-03-24 Genentech, Inc. Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines
GB201419108D0 (en) 2014-10-27 2014-12-10 Glythera Ltd Materials and methods relating to linkers for use in antibody drug conjugates
KR20170088905A (ko) * 2014-11-19 2017-08-02 이뮤노젠 아이엔씨 세포 결합 작용제-세포독성 작용제 접합체를 제조하기 위한 공정
BR112017011111A2 (pt) 2014-11-25 2017-12-26 Adc Therapeutics Sa conjugados de pirrolobenzodiazepina-anticorpo
BR112017012377A2 (pt) * 2014-12-09 2018-04-24 Abbvie Inc conjugados anticorpo-fármaco com inibidores de bcl-xl permeáveis à célula
EP3333191B1 (en) 2014-12-11 2020-09-09 Pierre Fabre Medicament Anti-c10orf54 antibodies and uses thereof
JP6676058B2 (ja) 2015-01-14 2020-04-08 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ヘテロアリーレン架橋したベンゾジアゼピン二量体、そのコンジュゲート、ならびに製造および使用方法
US9527871B2 (en) 2015-01-14 2016-12-27 Bristol-Myers Squibb Company Benzodiazepine dimers, conjugates thereof, and methods of making and using
WO2016148674A1 (en) * 2015-03-13 2016-09-22 Endocyte, Inc. Conjugates for treating diseases
JP6773677B2 (ja) 2015-03-17 2020-10-21 アローヘッド ファーマシューティカルズ インコーポレイテッド 改善されたジスルフィド含有アルキン連結剤
US9504694B2 (en) 2015-03-19 2016-11-29 Cellerant Therapeutics, Inc. Isoquinolidinobenzodiazepines
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
EA039619B1 (ru) * 2015-05-20 2022-02-17 Иммуноджен, Инк. Способ получения индолинобензодиазепиновых соединений
GB201510010D0 (en) 2015-06-09 2015-07-22 King S College London PDD and BPD compounds
CA2990030A1 (en) 2015-06-23 2016-12-29 Bristol-Myers Squibb Company Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses
CA2988806A1 (en) * 2015-06-29 2017-01-05 Immunogen, Inc. Conjugates of cysteine engineered antibodies
RS61452B9 (sr) 2015-06-29 2021-12-31 Immunogen Inc Anti-cd123 antitela i njihovi konjugati i derivati
ES2764548T3 (es) 2015-07-21 2020-06-03 Immunogen Inc Procedimientos de preparación de derivados de benzodiazepina citotóxicos
GB201514928D0 (en) 2015-08-21 2015-10-07 King S College London PDD compounds
US20180339985A1 (en) 2015-08-21 2018-11-29 Femtogenix Limited Pdd compounds
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
WO2017091745A1 (en) * 2015-11-25 2017-06-01 Immunogen, Inc. Pharmaceutical formulations and methods of use thereof
CA3010601A1 (en) 2016-01-08 2017-07-13 Bioalliance C.V. Tetravalent anti-psgl-1 antibodies and uses thereof
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
UY37111A (es) * 2016-02-05 2017-08-31 Ole Peter Veiby Conjugados de anticuerpo y fármaco dirigidos contra gcc
MA47022A (fr) * 2016-02-05 2018-12-12 Immunogen Inc Procédé efficace de préparation de conjugués agent de liaison cellulaire-agent cytotoxique
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
UA125510C2 (uk) 2016-03-25 2022-04-13 Сіджен Інк. Спосіб отримання пегильованої сполуки лікарський препарат-лінкер, де лікарським препаратом є ауристатин, та її проміжних сполук
US20200323991A1 (en) * 2016-03-29 2020-10-15 Endocyte, Inc. Pbd conjugates for treating diseases
JP7295640B2 (ja) * 2016-04-20 2023-06-21 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． アマニタ毒素の誘導体及びそれらと細胞結合分子との共役体
CA3021098A1 (en) 2016-04-21 2017-10-26 Abbvie Stemcentrx Llc Novel anti-bmpr1b antibodies and methods of use
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
TW201808936A (zh) 2016-05-18 2018-03-16 美商梅爾莎納醫療公司 吡咯并苯并二氮呯類及其共軛物
JP7049276B2 (ja) 2016-06-24 2022-04-06 メルサナ セラピューティクス インコーポレイテッド ピロロベンゾジアゼピンおよびその結合体
TW201808343A (zh) 2016-08-09 2018-03-16 美商西雅圖遺傳學公司 具有改善之生理化學性質之具自我穩定連接子之藥物結合物
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
US20200261470A1 (en) 2016-11-02 2020-08-20 Immunogen, Inc. Combination treatment with antibody-drug conjugates and parp inhibitors
EP3535300A1 (en) * 2016-11-03 2019-09-11 Bristol-Myers Squibb Company Activatable anti-ctla-4 antibodies and uses thereof
WO2018098258A2 (en) 2016-11-23 2018-05-31 Immunogen, Inc. Selective sulfonation of benzodiazepine derivatives
JP7244987B2 (ja) 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
US20210388102A1 (en) 2016-12-23 2021-12-16 Immunogen, Inc. Immunoconjugates targeting adam9 and methods of use thereof
WO2018129029A1 (en) 2017-01-04 2018-07-12 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CN110300765A (zh) 2017-01-24 2019-10-01 依奈特制药公司 Nkp46结合剂
SG11201906666QA (en) 2017-01-25 2019-08-27 Immunogen Inc Methods of preparing cytotoxic benzodiazepine derivatives
WO2018141959A1 (en) 2017-02-06 2018-08-09 Innate Pharma Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
UA125198C2 (uk) 2017-02-08 2022-01-26 Ейдісі Терапьютікс Са Кон'югати піролобензодіазепін-антитіло
EP3600443A1 (en) 2017-03-24 2020-02-05 Seattle Genetics, Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
WO2018183494A1 (en) 2017-03-31 2018-10-04 Immunogen, Inc. Cd19-targeting antibody-drug conjugates
CN106841192B (zh) * 2017-04-18 2019-05-03 乐凯（沈阳）科技产业有限责任公司 一种二氮杂卓结构指示剂检测甲醛方法及其应用
ES2926144T3 (es) 2017-04-18 2022-10-24 Medimmune Ltd Conjugados de pirrolobenzodiazepina
TW201839001A (zh) * 2017-04-20 2018-11-01 美商伊繆諾金公司 細胞毒性苯并二氮平衍生物及其綴合物
US10442809B2 (en) * 2017-04-20 2019-10-15 Immunogen, Inc. Methods for preparing substituted 12a,13-dihydro-6H-benzo[5,6][1,4]diazepino[1,2-a]indol-6-ones
JP7408396B2 (ja) 2017-04-20 2024-01-05 アーデーセー セラピューティクス ソシエテ アノニム 併用療法
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
WO2018229222A1 (en) 2017-06-14 2018-12-20 Adc Therapeutics Sa Dosage regimes for the administration of an anti-cd19 adc
EP3658568A4 (en) * 2017-07-26 2021-04-28 The University of Queensland COMPOUNDS CONTAINING A DISULPHIDE BOND AND ASSOCIATED USES
HRP20220311T1 (hr) 2017-08-18 2022-05-13 Medimmune Limited Konjugati pirolobenzodiazepina
BR112020004126A2 (pt) 2017-09-29 2020-09-08 Daiichi Sankyo Company, Limited conjugado anticorpo-derivado de pirrolbenzodiazepina
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
TW201922294A (zh) 2017-10-31 2019-06-16 美商伊繆諾金公司 抗體-藥物結合物與阿糖胞苷之組合治療
WO2019092148A1 (en) 2017-11-10 2019-05-16 Innate Pharma Antibodies with functionalized glutamine residues
US11638760B2 (en) 2017-11-27 2023-05-02 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
US11793885B2 (en) 2017-12-28 2023-10-24 Immunogen, Inc. Substituted benzo[5,6][1,4]diazepino[1,2-a]indoles for the treatment of proliferative disorders
WO2019140141A1 (en) 2018-01-12 2019-07-18 Immunogen, Inc. Methods for antibody drug conjugation, purification, and formulation
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
WO2019222130A1 (en) 2018-05-15 2019-11-21 Immunogen, Inc. Combination treatment with antibody-drug conjugates and flt3 inhibitors
TW202029980A (zh) * 2018-10-26 2020-08-16 美商免疫遺傳股份有限公司 Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途
SG11202104360YA (en) 2018-11-12 2021-05-28 Immunogen Inc Methods of preparing cytotoxic benzodiazepine derivatives
JP2022512936A (ja) 2018-11-12 2022-02-07 イミュノジェン・インコーポレーテッド 細胞傷害性ベンゾジアゼピン誘導体の調製方法
CN111393502B (zh) * 2019-01-03 2022-04-29 北京京东方技术开发有限公司 一种类肽及其制备方法和用途
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
KR20220010481A (ko) 2019-03-29 2022-01-25 이뮤노젠 아이엔씨 비정상 세포 성장의 억제 또는 증식성 질환의 치료를 위한 세포독성 비스-벤조디아제핀 유도체 및 세포결합제와 이의 접합체
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
EP4132588A1 (en) 2020-04-10 2023-02-15 Seagen Inc. Charge variant linkers
MX2023005873A (es) 2020-11-25 2023-06-05 Innate Pharma Tratamiento del cancer.
EP4308170A1 (en) 2021-03-18 2024-01-24 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
JP2024511360A (ja) 2021-03-18 2024-03-13 シージェン インコーポレイテッド 生体活性化合物の内部移行複合体からの選択的薬物放出
IL310764A (en) 2021-08-13 2024-04-01 Immunogen Inc Improved methods for the preparation of cytotoxic benzodiazepine derivatives
WO2023227660A1 (en) 2022-05-25 2023-11-30 Innate Pharma Nectin-4 binding agents
WO2024015830A1 (en) 2022-07-12 2024-01-18 Cytomx Therapeutics, Inc. Epcam immunoconjugates and uses thereof
WO2024026340A1 (en) * 2022-07-26 2024-02-01 Shattuck Labs, Inc. Combination therapy for treatment of ovarian cancer

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU11248A1 (ru) 1927-03-29 1929-09-30 В.С. Григорьев Способ очистки антрацена
US3453266A (en) 1966-03-14 1969-07-01 American Home Prod 1,2,5-benzothiadiazepine 1,1-dioxides
US3506646A (en) 1966-06-27 1970-04-14 American Home Prod Process for the preparation of 7h-pyrido (1,2-b)(1,2,5)benzothiadiazepine 5,5 - dioxides and pyrrolo(1,2-b)(1,2,5)benzothiadiazepine 5,5-dioxides
US3860600A (en) 1972-07-10 1975-01-14 Sterling Drug Inc Octahydropyrrido{8 2,1-c{9 {8 1,4{9 benzodiazepines
US3763183A (en) 1972-07-10 1973-10-02 Sterling Drug Inc 1,2,3,10,11,11a-hexahydro-5h-pyrrolo (2,1-c)(1,4)benzodiazepines
US3875162A (en) 1973-07-26 1975-04-01 Squibb & Sons Inc Certain 6H-pyrimido{8 1,2-c{9 {8 1,3,5{9 benzothiadiaza compounds
US4003905A (en) 1974-12-11 1977-01-18 E. R. Squibb & Sons, Inc. Diels-alder adducts of benzdiazepines
US4342771A (en) 1981-01-02 1982-08-03 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
JPS57131791A (en) 1980-12-31 1982-08-14 Fujisawa Pharmaceut Co Ltd Benzodiazepine derivative and its preparation
US4444688A (en) 1981-05-11 1984-04-24 Ciba-Geigy Corporation Imidazobenzothiadiazepines
US4678784A (en) 1984-04-11 1987-07-07 Mcneilab, Inc. Method for the treatment of LHRH diseases and conditions
JP2920385B2 (ja) 1988-08-18 1999-07-19 武田薬品工業株式会社 １，２，５‐ベンゾチアジアゼピン誘導体，その製造法および用途
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE275198T1 (de) 1991-12-02 2004-09-15 Medical Res Council Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken.
GB9205051D0 (en) 1992-03-09 1992-04-22 Cancer Res Campaign Tech Pyrrolobenzodiazepine derivatives,their preparation,and compositions containing them
DE69231123T2 (de) 1992-03-25 2001-02-15 Immunogen Inc Konjugaten von Zell-bindender Mittel und Derivaten von CC-1065
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
JPH08175990A (ja) 1994-12-19 1996-07-09 Mitsubishi Chem Corp Ｐｉ３キナーゼ阻害剤とその製造法
JPH08176070A (ja) 1994-12-19 1996-07-09 Mitsubishi Chem Corp ジデプシド誘導体及びｐｉ３キナーゼ阻害剤
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
WO1996033172A1 (en) 1995-04-20 1996-10-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors
GB9521987D0 (en) 1995-10-26 1996-01-03 Ludwig Inst Cancer Res Phosphoinositide 3-kinase modulators
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
PT780386E (pt) 1995-12-20 2003-02-28 Hoffmann La Roche Inibidores de metaloprotease de matriz
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
IL125954A (en) 1996-03-05 2003-06-24 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments having an antiangiogenic and/or vascular permeability reducing effect
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
KR20000067904A (ko) 1996-07-18 2000-11-25 디. 제이. 우드, 스피겔 알렌 제이 매트릭스 메탈로프로테아제의 포스피네이트계 억제제
KR20000068248A (ko) 1996-08-23 2000-11-25 디. 제이. 우드, 스피겔 알렌 제이 아릴설포닐아미노 하이드록삼산 유도체
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
ES2224277T3 (es) 1997-01-06 2005-03-01 Pfizer Inc. Derivados de sulfonas ciclicas.
ES2202796T3 (es) 1997-02-03 2004-04-01 Pfizer Products Inc. Derivados de acidos arilsulfonilaminohidroxamicos.
WO1998034915A1 (en) 1997-02-07 1998-08-13 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
HUP0000657A3 (en) 1997-02-11 2000-10-30 Pfizer N-arylsulfonyl-piperidine, -morpholine hydroxamic acid derivatives and pharmaceutical compositions containing them
DE69837529T2 (de) 1997-02-12 2007-07-26 Electrophoretics Ltd., Cobham Proteinmarker für lungenkrebs und deren verwendung
WO1999006587A2 (en) 1997-08-01 1999-02-11 Morphosys Ag Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex
CA2299355C (en) 1997-08-08 2005-09-27 Pfizer Products Inc. Aryloxyarylsulfonylamino hydroxamic acid derivatives
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
JP4462654B2 (ja) 1998-03-26 2010-05-12 ソニー株式会社 映像素材選択装置及び映像素材選択方法
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
US6156746A (en) 1998-08-25 2000-12-05 Bristol-Myers Squibb Company 1,2,5-benzothiadiazepine-1,1-dioxides with n-2 imidazolylalkyl substituents
EP1413582B1 (en) 1998-08-27 2006-03-15 Spirogen Limited Dimeric pyrrolobenzodiazepines
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
ES2213985T3 (es) 1998-11-05 2004-09-01 Pfizer Products Inc. Derivados de hidroxiamida de acido 5-oxo-pirrolidin-2-carboxilico.
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
IL144745A0 (en) 1999-02-10 2002-06-30 Astrazeneca Ab Quinazoline derivatives as angiogenesis inhibitors
FR2800507B1 (fr) 1999-10-27 2002-01-04 Valeo Systemes Dessuyage Commutateur electrique rotatif, notamment pour un moteur d'essuie-glace de vehicule automobile
JP3287409B2 (ja) 1999-10-28 2002-06-04 日本精工株式会社 ロック機構付シートベルト用リトラクターを備えたシートベルト装置
BR0015203A (pt) 1999-11-05 2002-07-16 Astrazeneca Ab Derivado de quinazolina, processo para a preparação de um derivado de quinazolina, composição farmacêutica, uso de um composto, e, processo para a produção de um efeito antiangiogênico e/ou redutor de permeabilidade vascular em um animal de sangue quente
EP1242401B1 (en) 1999-11-24 2006-12-27 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
AR034118A1 (es) 2000-02-15 2004-02-04 Sugen Inc Compuestos de 2-indolinonas sustituidas con pirroles inhibidoras de proteinquinasas; sus composiciones farmaceuticas e intermediarios de sintesis
JP2001247477A (ja) 2000-03-03 2001-09-11 Teikoku Hormone Mfg Co Ltd 抗腫瘍剤
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
US6403588B1 (en) 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
WO2001091780A1 (en) * 2000-05-26 2001-12-06 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
JP4458746B2 (ja) 2001-01-16 2010-04-28 グラクソ グループ リミテッド 癌の治療方法
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
WO2003018057A1 (fr) 2001-07-26 2003-03-06 Santen Pharmaceutical Co., Ltd. Remede contre le glaucome contenant en tant qu'ingredient actif un compose presentant un effet inhibiteur de la kinase pi3
US6703414B2 (en) 2001-09-14 2004-03-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Device and method for treating restenosis
US6908932B2 (en) 2001-10-24 2005-06-21 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
AU2002357667A1 (en) 2001-10-24 2003-05-06 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
JP2005509645A (ja) 2001-10-30 2005-04-14 ファルマシア・コーポレーション 炎症処置用のヘテロ芳香族カルボキサミド誘導体
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US20040092561A1 (en) 2002-11-07 2004-05-13 Thomas Ruckle Azolidinone-vinyl fused -benzene derivatives
BR0312650A (pt) 2002-07-10 2005-05-03 Applied Research Systems Derivados de benzeno fundido azolidinona-vinila
AU2003255529B2 (en) 2002-07-10 2008-11-20 Laboratoires Serono Sa Use of compounds for increasing spermatozoa motility
WO2004013093A2 (en) 2002-08-02 2004-02-12 Immunogen, Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
AU2003259163B2 (en) 2002-08-16 2008-07-03 Immunogen, Inc. Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
AU2003255845A1 (en) 2002-08-22 2004-03-11 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
DK1578446T3 (en) 2002-11-07 2015-06-29 Immunogen Inc ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT
FR2850654A1 (fr) 2003-02-03 2004-08-06 Servier Lab Nouveaux derives d'azepines tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1608664B1 (en) 2003-03-31 2009-01-28 Council of Scientific and Industrial Research Non-cross-linking pyrrolo[2,1-c][1,4]benzodiazepines as potential antitumour agents and process thereof
RU2338747C2 (ru) 2003-03-31 2008-11-20 Каунсил Оф Сайентифик Энд Индастриал Рисерч ДИМЕРЫ ПИРРОЛО [2, 1-c][1, 4] БЕНЗОДИАЗЕПИНА В КАЧЕСТВЕ ПРОТИВООПУХОЛЕВЫХ СРЕДСТВ И СПОСОБ ИХ ПОЛУЧЕНИЯ
EP1608663B1 (en) 2003-03-31 2008-11-05 Council of Scientific and Industrial Research Pyrrolo (2,1-c)(1,4) benzodiazepines dimers as antitumour agents and process thereof
RU2314309C2 (ru) * 2003-03-31 2008-01-10 Каунсил Оф Сайентифик Энд Индастриал Рисерч Пирроло [2.1-c][1.4] бензодиазепины, способ их получения и фармацевтическая композиция на их основе
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
CA2543318C (en) 2003-10-22 2013-01-08 B. Rao Vishnuvajjala Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
GB0404578D0 (en) 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
JP5166861B2 (ja) 2004-03-09 2013-03-21 スピロゲン リミティッド ピロロベンゾジアゼピン
GB0410725D0 (en) 2004-05-13 2004-06-16 Spirogen Ltd Pyrrolobenzodiazepine therapeutic agents
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
NZ580115A (en) 2004-09-23 2010-10-29 Genentech Inc Cysteine engineered antibody light chains and conjugates
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
US20080305044A1 (en) 2004-11-29 2008-12-11 Seattle Genetics, Inc. Engineered Antibodies and Immunoconjugates
EP2468304A3 (en) 2005-02-11 2012-09-26 ImmunoGen, Inc. Process for preparing stable drug conjugates
EP1902131B1 (en) 2005-07-08 2009-11-11 University of Zurich Phage display using cotranslational translocation of fusion polypeptides
US7772485B2 (en) 2005-07-14 2010-08-10 Konarka Technologies, Inc. Polymers with low band gaps and high charge mobility
ITRM20050416A1 (it) 2005-08-03 2007-02-04 Uni Degli Studi Di Roma Tor Vergata Derivati delle benzodiazepine e loro usi in campo medico.
CA2893252C (en) 2005-08-24 2018-05-29 Immunogen, Inc. Process for preparing antibody maytansinoid conjugates
US8637664B2 (en) 2005-10-05 2014-01-28 Spirogen Sarl Alkyl 4- [4- (5-oxo-2,3,5, 11a-tetrahydo-5H-pyrrolo [2, 1-c] [1,4] benzodiazepine-8-yloxy)-butyrylamino]-1H-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
EP1813614B1 (en) 2006-01-25 2011-10-05 Sanofi Cytotoxic agents comprising new tomaymycin derivatives
GB2453402B (en) 2006-02-13 2010-12-22 Council Scient Ind Res Novel bis-pyrrolo[2,1.-c] [1,4] benzodiazepine-anthraquinone conjugates and a process for the preparation thereof
ES2567402T3 (es) 2006-05-30 2016-04-22 Genentech, Inc. Anticuerpos anti CD22, sus inmunoconjugados y usos de los mismos
CN101687037B (zh) 2007-05-08 2013-07-10 健泰科生物技术公司 半胱氨酸改造的抗muc16抗体和抗体药物偶联物
PT2019104E (pt) * 2007-07-19 2013-12-03 Sanofi Sa Agentes citotóxicos compreendendo novos derivados de tomaimicina e sua utilização terapêutica
WO2009016647A1 (en) 2007-08-01 2009-02-05 Council Of Scientific & Industrial Research Pyrrolo [2,1-c][1, 4] benzodiazepine-glycoside prodrugs useful as a selective anti tumor agent
US20100003641A1 (en) 2007-08-15 2010-01-07 Hansen John P Dental crown system
JP2010539915A (ja) 2007-09-24 2010-12-24 ユニバーシティ・オブ・チューリッヒ 設計されたアルマジロリピートタンパク質
CN104524592B (zh) 2008-04-30 2018-06-05 伊缪诺金公司 交联剂和它们的用途
CN104258413A (zh) 2008-04-30 2015-01-07 伊缪诺金公司 有效的偶联物和亲水性连接体
GB0819095D0 (en) 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
SG2014009138A (en) 2009-02-05 2014-03-28 Immunogen Inc Novel benzodiazepine derivatives
MX2011008566A (es) 2009-02-12 2011-11-29 Janssen Biotech Inc Composiciones supercontigo basadas en el dominio de fibronectina tipo iii, metodos y usos.
JP5497152B2 (ja) * 2009-04-24 2014-05-21 エフ．ホフマン−ラ ロシュ アーゲー ブルトン型チロシンキナーゼの阻害薬
AU2010250536A1 (en) 2009-05-18 2012-01-19 Shuhei Nishiyama Meta-information sharing distributed database system in virtual single memory storage
KR20120080611A (ko) * 2009-10-06 2012-07-17 이뮤노젠 아이엔씨 효능 있는 접합체 및 친수성 링커
IL290617B2 (en) 2010-02-24 2023-11-01 Immunogen Inc Folate receptor 1 antibodies and immunoconjugates and uses thereof
AU2011239525B2 (en) 2010-04-15 2015-04-09 Medimmune Limited Pyrrolobenzodiazepines used to treat proliferative diseases
CN107019804A (zh) * 2010-04-15 2017-08-08 西雅图基因公司 靶向吡咯并苯并二氮杂卓结合物
CA2793890C (en) 2010-04-15 2017-08-15 Spirogen Developments Sarl Pyrrolobenzodiazepines and conjugates thereof
SG191965A1 (en) * 2011-02-15 2013-08-30 Immunogen Inc Methods of preparation of conjugates
EP2887965A1 (en) 2012-08-22 2015-07-01 ImmunoGen, Inc. Cytotoxic benzodiazepine derivatives
JP2015202619A (ja) * 2014-04-14 2015-11-16 独立行政法人 国立印刷局 凹版版面

Also Published As

Publication number Publication date
US20170044266A1 (en) 2017-02-16
EP3498303A1 (en) 2019-06-19
AU2012217719B2 (en) 2015-11-05
KR20190051081A (ko) 2019-05-14
US10570212B2 (en) 2020-02-25
ME02381B (me) 2016-06-20
CA2824864A1 (en) 2012-09-27
BR112013020540A2 (pt) 2017-03-21
JP2020143102A (ja) 2020-09-10
JP6049642B2 (ja) 2016-12-21
US8889669B2 (en) 2014-11-18
US20160108129A1 (en) 2016-04-21
EP2675479A1 (en) 2013-12-25
US20130302359A1 (en) 2013-11-14
IL279304A (en) 2021-01-31
EP3053600A1 (en) 2016-08-10
US8765740B2 (en) 2014-07-01
EP2675480A1 (en) 2013-12-25
PL2675479T3 (pl) 2016-09-30
IL227964A0 (en) 2013-09-30
US20190263924A1 (en) 2019-08-29
KR20200140939A (ko) 2020-12-16
JP2019142928A (ja) 2019-08-29
EP3666289A1 (en) 2020-06-17
US9434748B2 (en) 2016-09-06
MX2013009420A (es) 2013-12-16
US20120244171A1 (en) 2012-09-27
MX2013009417A (es) 2014-08-21
US10179818B2 (en) 2019-01-15
NZ613162A (en) 2015-10-30
TW201309674A (zh) 2013-03-01
IL279304B (en) 2022-07-01
CA3034596A1 (en) 2012-09-27
CN107335061B (zh) 2021-09-07
CN113896731A (zh) 2022-01-07
CA2824864C (en) 2019-04-09
EP2675479B1 (en) 2016-01-13
KR20140010067A (ko) 2014-01-23
US20180037659A1 (en) 2018-02-08
WO2012112708A1 (en) 2012-08-23
ES2717657T3 (es) 2019-06-24
EP3053600B1 (en) 2020-01-29
CN103687623B (zh) 2017-06-09
BR112013019913B1 (pt) 2021-01-05
JP2024026207A (ja) 2024-02-28
EP2675480B1 (en) 2018-12-26
SG191955A1 (en) 2013-08-30
IL227963A (en) 2017-08-31
BR112013020540B1 (pt) 2020-12-29
JP2016040298A (ja) 2016-03-24
CN103687623A (zh) 2014-03-26
CY1117340T1 (el) 2017-04-26
IL227964A (en) 2017-09-28
CA2825919A1 (en) 2012-08-23
EP2675481A1 (en) 2013-12-25
HUE043976T2 (hu) 2019-09-30
WO2012128868A1 (en) 2012-09-27
RU2013141829A (ru) 2015-03-27
JP2014521591A (ja) 2014-08-28
CN103702686A (zh) 2014-04-02
WO2012112687A1 (en) 2012-08-23
AU2017268554A1 (en) 2017-12-21
DK2675480T3 (en) 2019-04-15
AU2019264595A1 (en) 2019-12-05
BR112013019913A2 (pt) 2017-10-17
JP6216356B2 (ja) 2017-10-18
MX346635B (es) 2017-03-27
RU2017117634A3 (pt) 2020-08-26
IL227963A0 (en) 2013-09-30
KR20200141534A (ko) 2020-12-18
RU2013142179A (ru) 2015-03-27
RS58620B1 (sr) 2019-05-31
AU2012231640B2 (en) 2015-07-09
HRP20160164T1 (hr) 2016-03-11
RU2017117634A (ru) 2018-11-01
JP6526138B2 (ja) 2019-06-05
ES2567418T3 (es) 2016-04-22
AU2012231640A1 (en) 2013-05-02
IL293365A (en) 2022-07-01
JP6703632B2 (ja) 2020-06-03
JP2022009073A (ja) 2022-01-14
KR20140010076A (ko) 2014-01-23
UA120696C2 (uk) 2020-01-27
SG191965A1 (en) 2013-08-30
LT2675480T (lt) 2019-04-10
CN103702686B (zh) 2016-11-23
US20160324980A1 (en) 2016-11-10
US9840564B2 (en) 2017-12-12
PL2675480T3 (pl) 2019-07-31
SI2675479T1 (sl) 2016-04-29
SMT201600099B (it) 2016-04-29
SI2675480T1 (sl) 2019-05-31
RU2621035C2 (ru) 2017-05-31
US20120238731A1 (en) 2012-09-20
US20180002440A1 (en) 2018-01-04
TWI617555B (zh) 2018-03-11
JP5826863B2 (ja) 2015-12-02
RU2017131902A3 (pt) 2020-11-05
RS54667B1 (en) 2016-08-31
MX343337B (es) 2016-11-01
AU2016200752B2 (en) 2017-08-31
DK2675479T3 (en) 2016-04-11
CA3110544A1 (en) 2012-09-27
SG10201601046QA (en) 2016-03-30
CN107050468A (zh) 2017-08-18
US9353127B2 (en) 2016-05-31
MY183977A (en) 2021-03-17
ZA201305386B (en) 2015-11-25
US20140088089A1 (en) 2014-03-27
US9534000B2 (en) 2017-01-03
US9868791B2 (en) 2018-01-16
HUE028736T2 (en) 2017-01-30
RU2748733C2 (ru) 2021-05-31
CA2825919C (en) 2018-05-01
ZA201704808B (en) 2020-11-25
AU2012217719A1 (en) 2013-04-18
IL254055A0 (en) 2017-10-31
AU2017268554B2 (en) 2019-08-15
JP2014506892A (ja) 2014-03-20
RU2017131902A (ru) 2019-02-06
MY169448A (en) 2019-04-11
CY1121532T1 (el) 2020-05-29
HK1186686A1 (zh) 2014-03-21
AU2016200752A1 (en) 2016-02-25
SG10202007640VA (en) 2020-09-29
IL254128A0 (en) 2017-10-31
NZ613121A (en) 2015-05-29
US9169272B2 (en) 2015-10-27
HRP20190576T1 (hr) 2019-05-17
CA3034596C (en) 2021-05-25
US20150099874A1 (en) 2015-04-09
US10364294B2 (en) 2019-07-30
RU2631498C2 (ru) 2017-09-25
KR20190089048A (ko) 2019-07-29
CN107335061A (zh) 2017-11-10
JP2018027966A (ja) 2018-02-22

Similar Documents

Publication Publication Date Title
HRP20190576T1 (hr) Postupci pripreme konjugata
IL263973B (en) Protein-polymer-drug conjugates
HK1244183A1 (zh) Ivacaftor的氘化衍生物
HK1196257A1 (zh) -抗體結合物
IL228404A0 (en) Antibody-drug captures
EP2665733A4 (en) PREPARATION OF METAL-TRIAZOLATE NETWORKS
HUE047354T2 (hu) Ivacaftor deuterizált származékai
EP2670761A4 (en) PREPARATION OF METAL CATCHCHATE STRUCTURES
IL230758A0 (en) Conjugates of folate and albumin binding agents
IL231043A (en) vaccine
SG10201604667YA (en) Pharmaceutical preparation
EP2762167A4 (en) EASY SOLID PREPARATION TO TAKE
IL236312A0 (en) Preparation of 18f-flucyclobin
GB201119999D0 (en) Vaccine
GB201105298D0 (en) Pharmaceutical preparation
EP2763699A4 (en) VACCINE
EP2753629A4 (en) SAMPLE PREPARATION PROCESS
EP2684869A4 (en) PREPARATION OF 3-MERCAPOTOPROPIONATES
PL2691119T3 (pl) Preparat farmaceutyczny
GB2492817B (en) Blender
GB201120000D0 (en) Vaccine
IL228357A0 (en) solid preparation
PL395425A1 (pl) Sposób wytwarzania chlorowodorku 2-amino-N-tert-butylo-2- cyjanoacetamidu
GB201109614D0 (en) Odontalgic preparation
IL229109A0 (en) Cancer diagnosis